Synthesis of Azulene-Based Compounds for Targeting Orexin Receptors by Leino, Teppo
44/2018





















Recent Publications in this Series
25/2018 Elina Engberg
Physical Activity, Pregnancy and Mental Well-Being: Focusing on Women at Risk for Gestational 
Diabetes
26/2018 Anni Niskakoski
Molecular Alterations of Endometrial and Ovarian Tumorigenesis in Lynch  Syndrome Mutation 
Carriers and the General Population
27/2018 Katariina Maaninka
Atheroinflammatory Properties of LDL and HDL Particles Modified by Human Mast Cell 
Neutral Proteases
28/2018 Sonja Paetau
Neuronal ICAM-5 Regulates Synaptic Maturation and Microglia Functions
29/2018 Niina Kaartinen
Carbohydrates in the Diet of Finnish Adults - Focus on Intake Assessment and Associations with 
Other Dietary Components and Obesity
30/2018 Tuija Jääskeläinen
Public Health Importance of Vitamin D: Results from the Population-based Health 2000/2011 
Survey
31/2018 Tiina Lipiäinen
Stability and Analysis of Solid-State Forms in Pharmaceutical Powders
32/2018 Johanna Ruohoalho
Complications and Their Registration in Otorhinolaryngology – Head and Neck Surgery:  
Special emphasis in Tonsil Surgery Quality Registration
33/2018 Alok Jaiswal
Integrative Bioinformatics of Functional and Genomic Profiles for Cancer Systems Medicine
34/2018 Riikka Uotila
Let’s Get Cracking —Nut Allergy Diagnostics and Peanut Oral Immunotherapy
35/2018 Solomon Olusegun Nwhator
Association between a-MMP-8 Chairside Test for Chronic Periodontitis and Selected 
Reproductive Health Parameters
36/2018 Anna-Kaisa Rimpelä
Ocular Pharmacokinetic Effects of Drug Binding to Melanin Pigment and the Vitreous Humor
37/2018 Henna Vepsäläinen
Food Environment and Whole-Diet in Children - Studies on Parental Role Modelling and Food 
Availability
38/2018 Eeva-Liisa Tuovinen
Weight Concerns and Abdominal Obesity among Ever-Smokers: A Population-Based Study of 
Finnish Adults 
39/2018 Maheswary Muniandy
Molecular Effects of Obesity and Related Metabolic Risk Factors – A Transcriptomics and 
Metabolomics Approach
40/2018 Cristian Capasso
Development of Novel Vaccine Platforms for the Treatment of Cancer
41/2018 Ainoleena Turku
Discovery of OX1 and OX2 Orexin Receptor Ligands
42/2018 Johanna Pekkala
Occupational Class Differences in Sickness Absence – Changes Over Time and Diagnostic Causes
43/2018 Heli Paukkonen
Nanofibrillar Cellulose for Encapsulation and Release of Pharmaceuticals
Synthesis of Azulene-Based Compounds for 
Targeting Orexin Receptors
TEPPO O. LEINO
dissertationes scholae doctoralis ad sanitatem investigandam 
universitatis helsinkiensis 44/2018
DRUG RESEARCH PROGRAM
DIVISION OF PHARMACEUTICAL CHEMISTRY AND TECHNOLOGY
FACULTY OF PHARMACY
DOCTORAL PROGRAMME IN DRUG RESEARCH 
UNIVERSITY OF HELSINKI
Drug Research Program








To be presented, with the permission of the Faculty of Pharmacy of the University of 
Helsinki, for public examination in Auditorium 2, Info Centre Korona,
on August 16th 2018, at 12 noon.
Helsinki 2018
Supervised by Docent Erik Wallén, PhD
Drug Research Program




Professor Jari Yli-Kauhaluoma, PhD
Drug Research Program




Reviewed by Professor Jouko Vepsäläinen, PhD
School of Pharmacy
Faculty of Health Sciences
University of Eastern Finland
Kuopio, Finland





Opponent Professor Petri Pihko, PhD
Department of Chemistry
Faculty of Mathematics and Science
University of Jyväskylä
Jyväskylä, Finland
Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam Universitatis Helsinkiensis





Cover image by Lassi Leino
Hansaprint Oy
Helsinki 2018
“Genius is one percent inspiration and ninety-nine percent perspiration.”
Thomas A. Edison
Abstract
Orexin peptides, orexin-A and orexin-B, and orexin receptor 1 and orexin receptor 2 form 
the orexin signaling system. The most studied part of the orexin system is its key role in 
sleep-wake regulation, although it is linked also to other physiological functions, such as 
addiction and nociception. To date, a large number of orexin receptor antagonists have
been developed with one, suvorexant, having reached the market in the treatment of 
insomnia. However, much less attention has been paid to the development of small-
molecular agonists of the orexin receptors, and only a few are known in the literature.
Agonists might be beneficial for patients with narcolepsy or certain types of cancers.
The aim of this thesis was to develop small molecules based on the azulene scaffold 
for targeting orexin receptors. Azulene is an unexplored ring structure in medicinal 
chemistry, however, it resembles other bicyclic aromatics such as indole and naphthalene,
which are frequently found in drug molecules. The small number of existing general 
synthetic routes for azulenes possessing three or more substituents has most likely 
hindered the use of azulene-based compounds in medicinal chemistry. Due to this, the
study was initiated by developing two different synthetic routes to access 1,3,6-
trisubstituted azulenes.
In the developed methods, the azulene scaffold was first synthesized from simple, 
readily available and inexpensive starting materials. Then the scaffold was functionalized
via versatile synthetic handles, such as a halogen atom or a formyl group, which allow a
facile generation of compound series. The efficiency of the synthetic routes was 
demonstrated with test substances, which gave good overall yields.
The developed methods were used in the synthesis of azulene-based compounds, 
whose biological activity was assessed on the orexin receptors. The first series of 
compounds was based on the results from virtual screening of the library of 70 000 
synthetically accessible azulene-based compounds. The second series was designed based 
on the results from the biological evaluation of the first series.
With this approach, novel azulene-based ligands for orexin receptors were identified.
The two most promising binders had Ki values in the low micromolar range and five other
compounds acted as weak orexin receptor agonists. In addition, compounds potentiating 
the response of orexin-A to OX1 receptors in a concentration-dependent manner were 
discovered. These novel azulene-based compounds offer an interesting starting point for 
further development of antagonists, agonists and potentiators for orexin receptors.
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1.1 The orexin system
1.1.1 Orexin peptides and receptors
Orexin peptides, orexin-A and orexin-B, form the orexin signaling system together with 
orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). Two research groups
independently found the orexin peptides and their receptors in 1998. Sakurai et al. 
observed that the peptides they discovered are connected to feeding behaviour in rats.1
Thus, they decided to name the peptides orexins after the Greek word orexis, meaning
appetite. Around the same time de Lecea et al. found a mRNA sequence encoding the
precursor of the orexin peptides in hypothalamus.2 They called the resulting peptides as 
hypocretins: hypo since they were found from the hypothalamus, and cretin since they 
were partially analogous with the gut hormone secretin. Both terms orexin and hypocretin 
occur in the literature when referring to these peptides, and the term orexin is used in this 
thesis.
The orexin system is best known for its important role in sleep-wake regulation, but it 
has also been linked with other physiological functions, such as feeding behavior,1
nociception3 and reward.4 The central role of the orexin system in sleep-wake regulation 
has been observed from its connections to narcolepsy. Originally this was noticed in
narcoleptic dogs, which had a disruptive mutation in their OX2R gene.5 Later studies with 
knockout mice have supported the connection between narcolepsy and dysfunction of the 
orexin system, and these studies have suggested that OX2R has a more important role in 
type 1 narcolepsy than OX1R.6–8 In addition, the link between narcolepsy and orexin 
system has been verified in humans: A majority of narcolepsy patients with cataplexy 
have very low orexin-A levels in cerebrospinal fluid, when compared to healthy subjects.9
Narcoleptic humans also lack most of the orexin-producing neurons.10
The effect of the orexin peptides is transmitted through the G protein-coupled orexin 
receptors, OX1R and OX2R, which have seven transmembrane domains (TM1-7) 
connected by three intra- and three extracellular loops, and the C-terminus is intracellular 
and the N-terminus extracellular. In humans OX1R and OX2R consist of 425 and 444 
amino acids, respectively, and their complete sequences are 64% identical.1 Binding of the 
orexin peptides to the receptors activates many signaling pathways.11 One central response 
is an increase in the intracellular Ca2+ levels, which is caused by phospholipase C (PLC)
mediated release of intracellular Ca2+ stores and protein kinase C (PKC) mediated Ca2+
influx across the plasma membrane. The measurement of Ca2+ elevation is widely used in 
orexin receptor activation studies.
The two orexin receptors are mainly located in various regions of the central nervous 
system (CNS), where the receptor subtypes are differentially expressed.12 In addition, 
orexin responses have also been reported in the periphery.13 Interestingly, it has been 
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reported that certain types of cancer, such as colon cancer, have begun to express orexin 
receptors, whose activation would induce apoptosis.14,15 Thus orexin receptors are a
potential target also for cancer treatment.
Orexinergic neurons are located in the lateral hypothalamic and nearby regions. Orexin 
peptides are enzymatically cleaved from prepro-orexin, which is the orexin precursor 
consisting of 131 amino acids.1,16 Orexin-A is a 33 amino acid long peptide containing
two disulphide bridges between the cysteins (Cys6–Cys12, Cys7–Cys14), and
pyroglutamic acid at the N-terminus (Figure 1). Orexin-B is the shorter one of the orexin 
peptides, consisting of 28 amino acids not bearing any bridging within the structure. Both 
orexin peptides have C-terminal amide groups. The NMR structures of the orexin peptides 
in a buffered aqueous environment have shown that orexin-A forms three α-helical 
segments (residues 6–9, 16–23 and 25–32) and orexin-B two (residues 7–19 and 23–28),
respectively.17,18 Orexin-A can take either a bent or an extended conformation, whereas
orexin-B only exists in a bent conformation.
Figure 1 Primary structures of orexin-A and orexin-B. Conserved amino acids are highlighted 
with red color.
Orexin-A binds to both receptors with high affinity, whereas orexin-B has the same 
affinity to OX2R as orexin-A, but the binding affinity to OX1R is about ten times weaker. 
Furthermore, orexin peptides suffer from poor pharmacokinetic properties, typical to 
peptides. These include low blood-brain barrier (BBB) permeability,3,19 low 
bioavailability in oral administration,3 and rapid metabolism.20
The essential binding interactions of orexin peptides to the orexin receptors have been 
investigated in mutation and truncation studies of the peptides. Truncation studies have 
suggested that the C-terminus of the orexin peptides is fundamental for the receptor 
activation, since both peptides can be shortened down to 19 amino acid residues from the
N-terminus with only a small reduction in potency.21–23 Thirteen of these 19 amino acid
residues are in fact identical in both peptides (highlighted with red color in Figure 1).
Additionally, truncation from the C-terminus, or changing the primary amide to a carboxyl 
group, has resulted in the loss of activity of orexin-B.22
The C-terminus of orexin-A consists mainly of amino acid residues with hydrophobic 
side chains, which cause one side of the α-helical C-terminus to be highly lipophilic
(Figure 2).18,24 Three residues with hydrophobic side chain (Leu20, Ile30, Leu31) have 
been suggested to be significant for the receptor activation in the alanine point mutations
with truncated orexin-A peptides.21,23,25 The activity has also been lost after replacing
Thr32 with alanine. The corresponding residues exist in orexin-B as well, and point 
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mutations of these residues cause similar effect as in orexin-A.22 However, the results of 
the mutagenesis studies should be interpreted with caution, as the change in activity can be 
caused by a conformational change of the peptide, and not necessarily as a lack of the 
essential interaction between the receptor and the peptide.
Figure 2 Illustration of the hydrophobicity of orexin-A. Brown color represents hydrophobic 
areas and blue color hydrophilic. The intensity of the color depicts the strength of the 
property. (Figure kindly provided by L. Karhu)
In addition to mutations in orexin peptides, orexin receptors have been mutated to reveal
the binding site and important interactions between the orexin receptors and their ligands,
both antagonists and endogenous orexin peptides.26–29 The binding site of small-molecular 
antagonists was confirmed by recently published crystal structures of the human OX1
receptor with antagonists suvorexant (1) and SB-674042 (2) (Figure 3), and OX2 receptor 
with suvorexant.30,31 Suvorexant binds to the orthosteric location, which is highly 
conserved in both receptor subtypes. In the crystal structures, Ser103/Thr111 and 
Ala127/Thr135 are the only amino acids, which differ in OX1R/OX2R, respectively, at a 
distance no further than 4 Å from suvorexant. Also 2 occupies the same area as suvorexant 
in OX1R.
Figure 3 Dual orexin receptor antagonist suvorexant (1) and OX1R selective antagonist SB-
674042 (2).
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To this date the orexin receptors have not been crystallized with orexin peptides, and even 
though mutagenesis and computational studies have given some hints, the binding site and 
the bioactive conformation of the peptides remain unclear.24,26,27 Identification of the 
binding sites and interactions is important in order to develop novel small-molecular 
ligands for the orexin receptors.
1.1.2 Ligands of the orexin receptors
The orexin receptors are attractive drug targets for developing both agonists and 
antagonists. After discovery of the receptors and their link to sleep-wake regulation,
development of small-molecular ligands for the receptors has been of interest for the 
pharmaceutical industry. Several pharmaceutical companies have developed orexin 
receptor antagonists as a novel treatment for insomnia, which is a common sleep disorder
and the current pharmacological treatment is mainly based on positive allosteric
modulators of GABAA receptor and sedative antidepressants.32 GABAA modulators are
intended only for short-term use and they have several side effects, such as amnesia, 
rebound insomnia and addiction. Also sedative antidepressants have many side effects 
depending on the main mechanism of action of the drug.
Orexin receptor antagonists can be divided in three groups based on their binding 
affinities: OX1 selective orexin receptor antagonist (1-SORA), OX2 selective orexin 
receptor antagonist (2-SORA) and dual orexin receptor antagonist (DORA). Development 
of 2-SORAs and DORAs as a new class of hypnotics has gained major attention until 
now, since the role of OX2R in sleep-wake regulation is more significant than of OX1R.
Initially the focus of the development was in DORAs, and many DORAs, such as
almorexant (3)33,34 and SB-649868 (4)35, have shown to be effective in the treatment of 
insomnia in both animal models and humans (Figure 4). DORAs seem to promote
physiological sleep resembling sleep architecture, unlike GABAA receptor modulators, 
which tend to alter it.36,37 Possible induction of narcoleptic symptoms has been a major
concern regarding the orexin receptor antagonists, but fortunately it seems the symptoms 
are not promoted.34
The first orexin receptor antagonist suvorexant (1) was approved by the U.S. Food and 
Drug Administration (FDA) for sale for the treatment of insomnia in USA in 2014.38 It is
still the only one on the market, even though several other antagonists have been or are 
currently in clinical trials. In recent years there has been an increasing interest in
developing 2-SORAs, since antagonism of OX2 receptor alone has been reported to be
sufficient in promoting sleep both in animals and humans.39 However, the literature is still 
inconsistent regarding which compounds, 2-SORAs or DORAs, are optimal in promoting
sleep with physiological sleep architecture.40,41 Inconsistencies between the studies could 
derive from differences in the test setups, different pharmacokinetic properties of the 
compounds, and possibly also other physiological targets of some compounds. The 
structures of three 2-SORAs, compounds JNJ-10397049 (9),42 MK-1064 (10)39 and TCS-
OX2-29 (11),43 are presented in Figure 4.
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Figure 4 Structures and Ki values of dual orexin receptor antagonists 3 and 4, selective OX1
receptor antagonists 5–8 and selective OX2 receptor antagonists 9–11.
As described previously, orexin receptors are also involved in other physiological 
functions than sleep-wake regulation. Thereby, antagonists of the receptors might have 
other applications as well. 1-SORAs have been of particular interest in search for other 
possible targets, since they are largely ineffective to induce sleep.40,41 They might have 
potential in the treatment of various mental disorders, such as anxiety and panic, as well as 
addictive disorder. For example, the first known 1-SORA, SB-334867 (5) has blocked 
panic responses in rat panic model44 and it has also reduced opioid withdrawal (Figure 
4).45 Another 1-SORA, ACT-335827 (6), has shown anxiolytic effects in rats without 
affecting motor coordination or cognitive functions.46 Even though 5 is a widely used tool
compound in research, it has disadvantageously several off-targets.47 Recently, a highly 
potent and selective OX1 receptor antagonist 7 has been developed to act as a more 
applicable tool compound.48 Additionally, a morphinan-based series of potent and 
selective 1-SORAs has been published in 2017.49 From this series, the most potent 
compound 8 has been shown to suppress morphine withdrawal symptoms in mice.
A common feature among the orexin receptor antagonist structures is two aromatic 
moieties, which are attached to each other with a linker usually containing an amide or a
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urea functionality.50–52 Quite often the aromatic moieties are biaryls or fused bicyclic 
aryls, as shown in Figure 3 and Figure 4.
So far, when compared to antagonists, orexin receptor agonists have gained a minor 
attention in drug development. The best known agonists are the native peptide ligands, 
orexin-A and orexin-B, but the poor pharmacokinetic properties hamper their use as drugs
or research tools. In addition to the orexin peptides themselves, truncated and/or mutated 
orexin peptides have been shown to be orexin receptor activating ligands. However, being 
peptides, they suffer from the same limitations as the orexin peptides, which emphasizes 
the need for novel and potent small-molecular orexin receptor agonists with good 
pharmacokinetic properties. Especially blood-brain barrier permeability is important for 
CNS agents. Small-molecular agonists could be useful as chemical probes in studying the 
function of orexin, particularly in vivo. Agonists might also show potential as therapeutic 
compounds in the treatment of daytime sleepiness, especially in narcolepsy, or certain
types of cancer.
Narcolepsy is a chronic sleep disorder with excessive daytime sleepiness and 
unexpected sleep attacks.53 In type 1 narcolepsy, patients also have cataplexy, which
means sudden loss of muscle tone often triggered by strong emotions. Type 2 narcolepsy 
is then narcolepsy without cataplexy. Disorder in the orexin system has been connected to
type 1 narcolepsy.9 Curative therapy for narcolepsy is still lacking and the current 
pharmacological treatment is only relieving symptoms by CNS stimulating drugs, such as 
modafinil and methylphenidate.53 Additionally, certain antidepressants, like selective 
serotonin reuptake inhibitors (SSRIs), can be used in the treatment of cataplexy
symptoms.
To date, only a few series of non-peptide orexin receptor agonists have been published. 
Nagahara et al. were the first ones to report a potent small-molecular OX2 receptor agonist 
12 in 2015 (Figure 5).54 In search for an agonist they carried out a high throughput 
screening on OX2R with ca 250 000 druglike compounds, followed by the synthesis of
more than 1000 compounds. The sulphonamide group appeared to be essential for the 
receptor activation of 12, since replacing the group with amide resulted in loss of activity.
Also the synthesis of 13, a structural analogue of 12, has been reported in the same 
publication (Figure 5).54 Compound 13 appeared nearly as potent as 12 but has improved 
aqueous solubility and was therefore selected for further evaluation in animal models.55
Narcolepsy symptoms of prepro-orexin knockout mice were relieved after peripheral 
administration of 13. To further support the mechanism of action, no effect was observed 
in orexin receptor deficient mice, but in wild-type mice 13 promoted wakefulness. 
Together these results suggest that both narcolepsy and daytime sleepiness could be 
treated with orexin receptor agonists. However, a major drawback for the further 
development of 13 is its limited efficacy in vivo.
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Figure 5 The structures of the reported orexin receptor agonists 12–15. Compound 16 is an 
allosteric positive potentiator of the orexin receptor.
In addition, two series of orexin receptor agonists have been patented.56,57 The first series 
is based on the 1,3-dihydrobenzimidazol-2-imine scaffold, and the compounds of the
second series are 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione derivatives.
Compounds 14 and 15 were the most promising ones from each series (Figure 5), but the 
agonist activity of these compounds has only been reported superficially. Later, Turku et 
al. have studied biological activity of the compound 14 in more detail.58 They found
compound 14 to be a weak orexin receptor partial agonist with cytotoxic properties, which 
restricts its use as orexin receptor agonist. Furthermore, Turku et al. have developed a 
pharmacophore model to discover orexin receptor ligands, based on which they have 
identified four weak partial agonists of the orexin receptors.59
Positive orexin receptor potentiators are compounds enhancing the effects of 
endogenous orexin peptides. Potentiators could possibly be applied as a treatment of 
conditions caused by low levels of endogenous peptides. The potentiators would amplify 
the effect of the orexin peptides only when they are released physiologically, and therefore 
less side effects compared to agonists could be expected. Lee et al. have published the first
series of allosteric orexin receptor potentiators identified in a microarray-based cell-
binding screening and further optimization of peptoids, in which the aim was to find 
orexin receptor activators.60 The best compound 16 showed approximately two-fold 
potentiation of EC20 of orexin-A on orexin receptors.
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1.2 Azulene
1.2.1 Structure and properties of azulene
Azulene (17) is an aromatic nonalternant hydrocarbon consisting of a five-membered ring 
fused to a seven-membered ring (Figure 6). Azulene is a structural isomer of naphthalene
(19) as they both have the same molecular formula C10H8. However, the physicochemical
properties of these two compounds differ considerably from each other. One indication of 
this is the color of the compounds: naphthalene is white, whereas azulene has a distinctive 
deep blue color. In fact, the name azulene is a derivative from Spanish word azul, which 
means blue.
Figure 6 Azulene (17), guaiazulene (18), naphthalene (19) and indole (20).
The blue color of azulene derives from the exceptionally small energy difference between 
the ground state (S0) and the first excited state (S1) of the molecule, and unusually large 
energy gap between the first and the second excited states.61–63 The electron distribution of 
azulene differs remarkably between the highest occupied molecular orbital (HOMO) and 
the lowest unoccupied molecular orbital (LUMO) leading to the reduction in the repulsion 
forces between the electrons in these orbitals, which in turn explains the unusually small 
S0–S1 energy gap (Figure 7). Furthermore, the probability of the electron location is 
similar in the HOMO and LUMO+1, which explains the increase in the energy of the 
second excited state. Substituents of the azulene scaffold influence the color, which can 
vary all the way from purple to red within the visible light spectrum, depending on the 
position and nature of the substituent. The color changes as a result from either stabilizing 
or destabilizing effect of the different substituents on HOMO, LUMO and LUMO+1,
which results in changes in the energy gaps between the states. In addition to color, 
another unusual character of azulene is that it exhibits fluorescence from the second 
excited state (S2 → S0).64,65
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Figure 7 Relative distribution of electron density for azulene and naphthalene in their ground 
state (S0) and first excited state (S1).
The illustration of the HOMO of azulene also shows that the most probable location of the 
electrons is on the five-membered ring of azulene, while the seven-membered ring is
electron-deficient. Thus, it can be considered that azulene is formed of a
cyclopentadienide ion and a tropylium ion, which both are aromatic structures also on 
their own (Figure 8). This highlights the charge distribution between the rings, and it 
explains also why azulene has a dipole moment (1.08 D, measured in benzene).66 Azulene 
can be considered as an isostere of indole (20, Figure 6), since both structures have an
electron-rich five-membered ring fused to a larger ring, and a dipole moment between the
rings.
Figure 8 Azulene has two Kekulé resonance structures as well as several others with separated 
charges. When the negative charge is drawn to be located on the five-membered ring 
and the positive charge on the seven-membered, azulene is formed of two fused 
aromatic structures: a cyclopentadienide ion and a tropylium ion.
The electron distribution of azulene affects its reactivity. The electron rich five-membered 
ring readily reacts with electrophiles at the 1- and 3-position,67 and these positions can be 
functionalized using electrophilic aromatic substitution reactions, such as Vilsmeier–
Haack formylation and Friedel–Crafts acylation.68,69 However, the regioselectivity of these 
reactions between the 1- and 3-position is usually poor. Compared to the 1- and 3-position
functionalization of the 2-position is more challenging, although it can be substituted with 
boronic acid pinacol ester in an iridium-catalyzed reaction.70 The boronate group can be 
then converted to many other functionalities.70–72
The reactivity of the five-membered ring is also important from the metabolic point of 
view, since, as expected, it is prone to enzymatic oxidation. In the metabolic studies of 
azulene in rats, the sulphate conjugate of 1-hydroxyazulene has been identified as the main 
metabolite in urine.73 Interestingly, 1-hydroxyazulene is extremely unstable compound,74
whereas 2-hydroxyazulene is stable and shows keto-enol tautomerism.75 In order to
prevent the undesired metabolic activity of azulene in medicinal chemistry applications, it 
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might be beneficial to substitute either both 1- and 3-positions, or at least one of these with 
a deactivating group.
The electron-deficient seven-membered ring of azulene reacts with nucleophiles at the 
4-, 6- and 8-position,76–78 and also other reaction types to substitute these positions have 
been reported.79,80 Often these reactions either suffer from the lack of regioselectivity or 
they require certain substitution on the azulene scaffold. The 5- and 7-position of azulene
are also nucleophilic to some extent, since they have been reported to react with 
electrophiles after the more nucleophilic 1- and 3-positions have already been
substituted.81,82 Thus, in many cases the most convenient way for substitution of the 
seven-membered ring is to introduce the desired substituent in certain position already in
the synthesis of the azulene ring, as described more in detail in the next section.
1.2.2 Synthesis of the azulene ring
Although azulene is a commercially available compound, its use in synthetic chemistry is 
limited by the relatively high price as well as the fact that the seven-membered ring of 
azulene is difficult to selectively substitute without a suitable synthetic handle. The natural 
product guaiazulene (18, Figure 6) is commonly used as starting material, since it is 
readily available and inexpensive. Even though the methyl and isopropyl groups of 
guaiazulene can be exploited by substituting the seven-membered ring,83 on the other hand
they limit the substitution pattern of azulene derivatives. Since chemical suppliers can 
provide only few other, relatively expensive substituted azulenes, in the synthesis of 
azulene derivatives the azulene ring is usually constructed from simpler starting materials. 
The formation of the bicyclic ring structure also allows introduction of various
substituents as synthetic handles for further functionalization of the azulene scaffold. 
Certain important synthetic methods for azulene ring formation are described herein. Also 
the reaction mechanisms of the methods used in our study are provided.
In 1955 Ziegler and Hafner reported the first synthetic method for forming the azulene 
ring without any dehydrogenation step.84–87 The synthesis begins from the formation of 
(2,4-dinitrophenyl)pyridinium chloride (22) from pyridine (21) and 1-chloro-2,4-
dinitrobenzene (Scheme 1A). In the next step the pyridinium ring is opened with an amine 
derivative and when using dimethylamine, the intermediate 23 is obtained. The
intermediate 23 reacts with cyclopentadienyl anion, which after thermal cyclization gives 
azulene (17). The method allows introduction of various hydrocarbon substituents in the 
seven-membered ring when using variable pyridine derivatives as starting materials.
Modified reaction conditions for the Ziegler–Hafner method have been reported in the 
literature. An interesting modification utilizes alkyl pyridinium derivatives (Scheme 
1B).88–90 Alkyl pyridinium readily reacts with cyclopentadienyl anion and no additional 
amine is needed for the ring opening. After thermal cyclization the azulene derivatives are 
obtained. The proposed reaction mechanism for the azulene ring formation is presented in 
Scheme 1C. The yields of the Ziegler–Hafner azulene synthesis vary a lot depending on
the used pyridine derivatives and the reaction conditions. Bauer and Müller-Westerhoff
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have modified the Ziegler–Hafner method to synthesize 6-dimethylaminoazulene from 4-
pyrone instead of using pyridine as a starting material.91
Scheme 1 Two modifications of the Ziegler–Hafner azulene synthesis (A and B) and the 
proposed reaction mechanism (C). Reagents and conditions: (a) 1-Chloro-2,4-
nitrobenzene, 90 °C, 4 h; (b) Me2NH, pyridine, 0 °C, 20 min, rt, 12 h; (c) i) 
Cyclopentadiene, NaOMe, ii) 125 °C, 4 d, 51–59% from 21; (d) 1-Bromobutane, 
EtOH, reflux, overnight, 68% (26), 98% (27); (e) Cyclopentadiene, NaH, DMF, rt, 
1 h, reflux, 3 h, 66% (28), 81% (29).
The azulene ring can also be synthesized from unsaturated seven-membered rings, such as 
tropone and cycloheptatriene derivatives. 2-Halo- and 2-methoxytropones react with 
malonic acid derivatives to form 1,2,3-trisubstituted azulenes, such as 33, in the presence 
of a base (Scheme 2A).92,93 These substituents can also be removed, if needed.
Additionally, substituents, such as a bromine atom or an alkyl group, can be introduced to 
the seven-membered ring with this method, starting from substituted 2-halotropones.94
However, the yields are low and substituted 2-halotropones are rarely commercially 
available. Tropones have also been shown to react with prop-2-
enylidenetriphenylphosphorane derivatives to form the azulene ring, the synthesis of 34
from 31 as an example.95
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Scheme 2 Synthesis of the azulene scaffold from tropone (A) and cycloheptatriene (B and C)
derivatives. Reagents and conditions: (a) Ethyl cyanoacetate, NaOEt, EtOH, rt, ca 
70% from 31; (b) (2-Ethoxyallylidene)triphenyl-λ5-phosphane, DMSO, rt, 12 h, 
60% from 31; (c) Trichloroacetyl chloride, Zn/Cu, Et2O, rt, 4 h, 58%; (d) CH2N2,
MeOH/Et2O, rt, 30 min, 85%; (e) LiCl, DMF, 110–120 °C, 6 h, 73%; (f) Et3N, THF, 
rt, 9 h, 95%; (g) Pyrrolidine, PhH, reflux, 12 h, 75%; (h) Trichloroacetyl chloride, 
Zn/Cu, POCl3, Et2O, rt, 20 h; (i) i) CH2N2, MeOH/Et2O, 0 °C → rt, 35 min, ii) 
DMF, rt, 12 h, 45% from 41; (j) i) iPr2Zn, CuOTf, HMPA, TMSCl, –100 °C, 6 h, ii) 
PhSeCl, –50 °C → 0 °C, 2 h, iii) H2O2, pyridine, 0 °C, 1 h, 62%; (k) i) NaBH4,
MeOH/CeCl3, 0 °C, 1.5 h, ii) Burgess reagent, THF, 0 °C, 1 h, iii) p-Chloranil, rt,
24 h, iv) MeB(OH)2, Pd(OAc)2, dpdb, K3PO4, PhMe, 100 °C, 24 h, 53%.
Cycloheptatriene (35) reacts with dichloroketene, prepared in situ by treating
trichloroacetyl chloride with activated zinc, to form intermediate 36 (Scheme 2B).96 The 
four-membered ring of 36 is expanded to a five-membered ring with diazomethane. 2-
Hydroxyazulene (38) is obtained after heating compound 37 in the presence of a lithium 
salt. The intermediate 37 can also be treated in other conditions to obtain various azulenes,
such as 1-(azulen-2-yl)pyrrolidine (40) from the treatment of 37 with trimethylamine 
followed by pyrrolidine. Carret et al. have employed the method for 7-
methylcycloheptatriene (41) as starting material (Scheme 2C).97 They have also modified 
the final steps of the route, which has allowed substitution of the 1- and 7-position of 
azulene.
The seven-membered ring of azulene can also be prepared from benzene ring using 
Büchner’s ring expansion method. Based on this, Scott et al. have developed a method for 
azulene synthesis, in which the bicyclic compound 47 is synthesized from the diazoketone
46 in the presence of a copper(I) catalyst (Scheme 3A).98 However, azulene (17) is
obtained in the following dehydrogenation step only in moderate yield.
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Scheme 3 Two ring expansion-annulation strategies for the synthesis of azulenes (A and B). 
The reaction mechanism to form 1-acetoxyazulene (51) from the diazo ketone 50
(C). Conversion of a triflate group to a boronate group (D). Reagents and 
conditions: (a) i) SOCl2, reflux, 2 h, ii) CH2N2, 0 °C, 2 h, rt, 1 h, 97%; (b) CuCl, 80 
°C, 8 h, 52%; (c) P2O5, CH3SO3H, 60 °C, 6 h, 30–50%; (d) HBr-SiO2, DCM, rt; (e) 
i) (COCl)2, PhH, 65 °C, ii) CH2N2, Et2O, 0 °C → rt, 69% from 48; (f) i) Rh2(t-
BuCO2)4, DCM, rt, 45 min, ii) DMAP, Ac2O, rt, 5 min, 64–72%; (g) i) Rh2(t-
BuCO2)4, DCM, rt, 45 min, ii) DMAP, Tf2NPh, rt, 10 min (h) 4,4,5,5-tetramethyl-
1,3,2-dioxaborolane, Pd(OAc)2, (o-biphenyl)PCy2, Et3N, THF, rt, 16 h, 45–51% 
from 50.
Kane et al. have modified the method reported by Scott et al. (Scheme 3B and C).99 The 
synthetic route begins from cinnamic acid (48) with a hydrobromination reaction followed 
by the preparation of the diazo ketone 50. The bromo ketone 53 is obtained after exposing
of the diazo ketone to the rhodium(II) catalyst, and the subsequent elimination reaction in
the presence of DMAP gives 1-hydroxyazulene (54). Since 54 is extremely unstable,74
acetic anhydride has been used to trap the hydroxy group to give the stable ester 51.
Instead of acetic anhydride Kane et al. have shown that the hydroxy group can also be 
trapped with N-phenyl-bis(trifluoromethanesulfonimide) to give triflate derivative 55
(Scheme 3D). However, the triflate 55 has also been characterized to be unstable, but it
can be converted to more stable pinacol boronate ester 56.100 Both functionalities can be 
used in Suzuki cross-coupling reactions.
The advantage of this method is that cinnamic acid derivatives can be easily prepared 
from various benzaldehydes using Knoevenagel condensation, and when varying the
substituents on the benzaldehydes, the final azulenes possess these substituents in the
seven-membered ring. Kane et al. have shown that the method tolerates a wide range of 
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substituents, such as halogens, nitro and alkyl groups, in the phenyl ring. However, the 
introduction of both a halogen atom at the seven-membered ring and a triflate group at the 
1-position lead to selectivity problems in Pd-mediated coupling reactions, since both
functionalities are equally reactive under Suzuki coupling conditions.100
In addition to the synthetic routes described above, other approaches are reported in 
the literature.101–104 Altogether, several methods for the synthesis of the azulene ring have 
been developed to date. Advantages and restrictions vary between the methods. Low 
overall yields, toxic and explosive reagents (e.g. diazomethane), availability and price of 
starting materials or difficulties to introduce substituents to seven-membered ring during 
the azulene scaffold formation are the major limitations in the previously described 
methods.
1.2.3. Azulene scaffold in medicinal chemistry applications
The azulene ring has not been intensively studied in medicinal chemistry so far, unlike its 
structural isomer naphthalene and its isostere indole.105 The antiulcer agent egualen 
sodium (57) is the only azulene-based drug on the market,106 and also some sulphonamide 
derivatives of guaiazulene, such as 58 and 59, have shown antiulcer activity (Figure 9).107
Egualen sodium has also been used as a starting point in the development of azulene-based
thromboxane A2 (TXA2) receptor antagonists as it has shown some TXA2 antagonist 
activity.108–110 As a result of the optimization process, 60 was found to be a potent TXA2
receptor antagonist without partial agonist activities.
Figure 9 Azulene derivatives with antiulcer activity: Egualen sodium (57) and sulphonamide 
derivatives of guaiazulene 58 and 59. Compound 60 is TXA2 receptor antagonist.
The azulene ring has been used as a bioisostere in medicinal chemistry applications. In 
this approach, compounds with known biological activities have been modified by 
replacing the unsaturated rings of the compounds with azulene (Figure 10). Löber et al. 
have studied the use of azulene as an arene bioisostere in the development of novel 
dopamine D4 receptor ligands for the treatment of erectile dysfunction.111,112 They have 
chosen dopamine receptor binding azaindole derivatives, such as 61, as the starting point,
and used azulene instead of the azaindole structure. Compound 62 showed subnanomolar 
binding and partial agonism to the D4 receptor. In a further study they focused on
functionalization of the 3-position of 62, and in in vivo studies compound 63 induced 
penile erection in rats.112
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Figure 10 Utilizing azulene ring as a bioisostere in medicinal chemistry. The unsaturated ring, 
which is replaced by azulene, is marked in red color.
The antidiabetic agent ipraglifozin (64) is a C-glucoside-based sodium-dependent glucose 
cotransporter 2 (SGLT2) inhibitor developed by pharmaceutical companies Astellas and 
Kotobuki.113 The same companies have also investigated azulene derivatives of 
ipraglifozin by replacing the benzothiophene with azulene for the same target.114 The most 
potent azulene-based compounds have shown SGLT2 inhibition at low nanomolar 
concentrations. Furthermore, the best compound 65 induced strong and sustained 
antihyperglycemic effect in diabetic rodents after oral administration.
Azulene derivatives have also been developed for cancer imaging. Cyclooxygenase-2
(COX-2) overexpression has been reported in several human cancer cell lines, such as 
breast115 and stomach cancers.116 Inspired by this, Nolting et al. have studied a known 
indole-based COX-2 inhibitor, indomethacin (66), and synthesized indomethacin like 18F-
labeled azulene derivative 67 as a radioactive COX-2 probe.117 In addition to cancer 
imaging, azulenes have been studied for their anticancer properties. Anticancer properties 
of retinoic acid (68) and its phenyl derivatives (e.g. 70) have been of interest for Asato et 
al., who have replaced a part of these molecules with azulene derivatives to form new 
compounds, such as 69 and 71. The resulting azulenic retinoids and retinobenzoic acid 
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analogs showed anticancer activity in the in vitro mouse fibroblast C3H/10T1/2 cell 
bioassay.118 However, the azulenic retinoids were less potent than 70.
Other azulene-based compounds with anticancer properties are azulenes with oxindole 
and azaoxindole moieties, which inhibited FMS-like tyrosine kinase 3 (FLT-3) at low
nanomolar concentrations making these compounds potential starting points in the 
development of a new class of antileukemia agents.119 Furthermore, azulene-indoles have 
shown in vitro activity against different human cancer cell lines.120 The structures of the 
most promising compounds from these studies, 72 and 73, are presented in Figure 11.
Figure 11 Azulene-based compounds with anticancer activities.
The natural product guaiazulene is used as an additive in cosmetics, such as lotions, 
although there is some evidence for its cytotoxic effects.121 Guaiazulene (18) and its 
derivative, stilbazulenyl nitrone (74) have been reported to have antioxidant 
properties.122,123 The amidine derivative of guaiazulene 75 has inhibited arterial 
contractions in vitro in isolated pig coronary arteries.124 The mechanism of action has been
partially explained by the inhibition of L-type Ca2+-channels and protein kinase C.
Another naturally occurring azulene derivative, chamazulene carboxylic acid (76), has an 
anti-inflammatory activity,125 likely due to its structural resemblance to the known non-
steroidal anti-inflammatory drug naproxen (77). Finally, some azulene-based compounds 
have acted as antimicrobial agents in in vitro studies.126,127
Figure 12 Azulene derivatives with various biological activities and the structure of naproxen 
(77).
To conclude, azulene can be considered as an interesting ring structure in drug discovery,
even though it has not been widely applied so far. Inscrutability can also be considered as 
an advantage, since novel azulene-based compounds are most likely still patentable, which 
is vital in drug development. Small amount of available synthetic routes to access azulenes 
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possessing three or more substituents is one reason that limits the use of azulenes in 
medicinal chemistry. Due to this there is a need for the development of general synthetic 
protocols towards multiply substituted azulenes. Novel synthetic approaches could enable 
making series of azulene-based compounds for discovering new interesting bioactivities.
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2 Aims of the study
The aim of the study was to develop small molecules for targeting orexin receptors, and in 
particular, to identify orexin receptor agonists. Mimicking of the C-terminus of orexin-A, 
which has been shown to be essential for the activation of the orexin receptors, was used 
as an approach in search for new orexin receptor ligands. The hydrophobic, bicyclic
azulene skeleton was reasoned to resemble the lipophilic side of the α-helical C-terminus
of orexin-A. Many known orexin receptor ligands, especially antagonists, were noticed to 
contain biaryls or fused bicyclic aryls, which suggests the orthosteric binding site of the 
receptor could form beneficial interactions with azulene as well. In addition, azulene is 
scarcely reported ring structure in medicinal chemistry, although it closely relates to other 
bicyclic aromatics frequently found in drug molecules. Thus, the study focused on 
investigating the potential of azulene as a scaffold for the orexin receptor targeting 
compounds.
The more specific aims of the study were:
To develop general regioselective synthetic protocols to access trisubstituted 
azulenes (Publications I and II).
To design and synthesize azulene-based compounds for targeting orexin receptors
and study their activity in in vitro (Publication III).
To further optimize azulene-based orexin receptor ligands to find compounds with
enhanced agonist activity to orexin receptors (Publication IV).
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3 Results and discussion
3.1 Synthesis of 1,3,6-trisubstituted azulenes
This study was initiated by developing general synthetic routes to access different 1,3,6-
trisubstituted azulenes. We aimed at developing methods, which would allow the
regioselective substitution of the azulene scaffold with the use of synthetic handles in the 
different substitution position. This approach enables an easy generation of compound
series for biological activity testing. Various reasons supported focusing on the 1-, 3- and 
6-positions of the azulene scaffold. First, the 1-, 3- and 6-positions are on different sides 
of the azulene scaffold. Second, the 1- and 3-positions are the most reactive ones of the 
azulene ring, and in order to enhance the stability of azulene derivatives, metabolic 
stability as an example, at least one of these positions should be substituted. Finally, the 
substitution of the seven-membered ring at the 6-position gives symmetrical azulene, in 
which the 1- and 3-position are identical and selectivity problems are not expected
between these positions.
3.1.1 Synthesis of the azulene scaffold
As the selective substitution of the seven-membered ring of azulene is problematic without 
a suitable synthetic handle, it is advantageous to introduce a synthetic handle to the ring
already during the formation of the azulene scaffold. Due to this, we first decided to 
investigate synthetic methods for construction of the azulene scaffold with suitable 
substituents on its 6-position. We chose 6-methylazulene (80) as the key intermediate for 
the first synthetic route (Publication I), since the methyl group can be further converted to 
other functionalities.128 6-Methylazulene has been previously synthesized from 1-butyl-4-
methylpyridinium bromide (79) and sodium cyclopentadienide with the Ziegler–Hafner
method.88
First, amine alkylation of 4-methylpyridine (78) with 1-butylbromide gave 79 in
quantitative yield (Scheme 4). In the following step of the reaction 6-methylazulene was 
obtained in 23% yield, which was comparable with the 27% yield reported in the 
literature.88 Several side products were formed in the reaction and they were difficult to 
separate from the product. Due to this we investigated whether the reaction conditions 
could be further optimized by varying concentration, solvent, base, temperature, reaction 
time, and heating regime using either conventional or microwave heating. The studied
methods and yields are shown in Table 1. The best combination of base and solvent 
appeared to be NaH and DMF. The use of other bases and solvents resulted in lower 
yields, likely due to incomplete deprotonation of cyclopentadiene and reduced solubility 
of the pyridinium salt. However, rapid heating to high temperatures with microwaves and 
lowering the concentration improved the yields. The increased temperature also shortened 
the reaction time significantly.
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Scheme 4 Synthesis of 6-methylazulene. Reagents and conditions: (a) 1-Bromobutane, EtOH, 
reflux, overnight, quant.; (b) Base, cyclopentadiene, 2.5–64% (Table 1).
Table 1 Conditions used in the optimization of 6-methylazulene synthesis.




1 rt, 1 h + reflux, 3 h NaH DMF 1.0 10 23
2 rt, 1 h + reflux, 3 h NaOH MeOH/THF 1:20 1.0 10 3.5
3 rt, 1 h + reflux, overnight NaOMe MeOH 1.0 10 2.5
4 rt, 1 h + reflux, 3 h NaH THF 1.0 10 6.0
5 rt, 1 h + reflux, 3 h NaH EtOH/THF 1:4 0.80 10 2.5
6 rt, 1 h + reflux, 3 h NaH DMF 0.50 10 44
7 rt, 5 min + mw, 170 °C, 30 min NaH DMF 0.25 2.5 57
8 rt, 5 min + mw, 152 °C, 30 min NaH DMF 0.25 2.5 45
9 rt, 5 min + mw, 200 °C, 30 min NaH DMF 0.25 2.5 59
10 rt, 5 min + mw, 170 °C, 30 min NaH DMF 0.10 1.0 64
11 rt, 5 min + mw, 170 °C, 30 min NaH DMF 0.050 0.50 52
12 rt, 10 min + mw, 170 °C, 30 min n-BuLi Hex/THF/DMF 1:1:2 0.25 2.5 25
13 rt, 15 min + mw, 170 °C, 30 min n-BuLi Hex/DMF 2.5:7.5 0.25 2.5 38
14 rt, 15 min + mw, 170 °C, 30 min n-BuLi Hex/DMF 1:9 0.10 1.0 60
a Concentration of 1-butyl-4-methylpyridinium bromide.
After optimizing the reaction conditions, the possibility to scale-up the synthesis of 6-
methylazulene was evaluated. Entry 9 was chosen as the starting point for the scale-up 
process. As the volume of microwave vials is limited, the reaction mixture was divided 
into ten separate microwave vials (10–20 mL) and they were run sequentially using the 
robotic instrumentation. After microwave heating, the contents of the vials were combined 
into two batches for workup and further into one for flash chromatography. In this way,
the 50 mmol scale was reached with an overall yield of 63% corresponding 4.5 g of pure
6-methylazulene. Additionally, we noticed that the heating time could be shortened from 
30 min to 15 min without affecting the purity or the yield.
We also tried to synthesize 6-haloazulene with the same method as 6-methylazulene by 
changing the starting material from 4-methylpyridine to 4-halopyridine. Unfortunately, 
these attempts failed. As a halogen atom is a versatile synthetic handle and can be 
exploited in many palladium-mediated coupling reactions,100,129–133 we decided to study an 
alternative method to furnish an azulene ring with halogen substituent. A few synthetic 
routes for 6-haloazulene derivatives can be found in the literature, but most of them 
include multiple steps with low overall yields.80,91,94,101 We chose the method reported by 
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Kane et al.,99 which directly gives an ester substituent linked to a hydroxy group at the 1-
position of the azulene scaffold. Thus, we decided to also study what kind of substituents 
could be introduced at the 1-position with the ester linker. Having a triflate group at the 1-
position was not an option for us, since it causes selectivity problems with the halogen 
atom at the 6-position in the later stages of the synthesis. Thus, the azulene derivatives
synthesized with this method are based on the 1-acyloxyazulene scaffold (Publication II).
The synthesis of the 6-chloro-substituted azulene scaffold was started from 4-
chlorobenzaldehyde (81) (Scheme 5). 4-Chlorocinnamic acid (82) was synthesized in 92% 
yield using Knoevenagel condensation. In the hydrobromination of the double bond of 82,
we used more practical and commercially available HBr in glacial acetic acid instead of 
gaseous HBr of the reported method.99 The reaction gave 98% yield, but the 4-day
reaction time was needed for a high conversion. Kane et al. used previously diazomethane 
in the synthesis of diazo ketone 84 and we aimed at replacing it with the less explosive 
(trimethylsilyl)diazomethane. After converting 83 to the corresponding acyl chloride,
(trimethylsilyl)diazomethane was added to generate the diazo ketone 84, applying a 
method reported in the literature.134 Optimization of the reaction conditions did not result
only in the use of safer reagents but also in an improved overall yield of the diazo ketone 
84 from cinnamic acid 82. Our method gave a 77% yield in comparison to the 61% yield 
in the literature.99
Scheme 5 Synthesis of 1-acyloxyazulene scaffold. Reagents and conditions: (a) Malonic acid, 
piperidine, pyridine, 105 °C, 21 h, 92%; (b) 33% HBr in glacial acetic acid, rt, 96 
h, 98%; (c) i) Oxalyl chloride, benzene, 65 °C, 18 h, ii) TMSCHN2, MeCN, 0–4 °C, 
24 h, 79%; (d) Rh2(t-BuCO2)4, rt, 1.5 h, ii) Appropriate electrophile, DMAP, rt, 5 
min, 62% (85), 40% (86), 33% (87), 40% (88), 14% (89), 51% (90), 25% (91), 32% 
(92).
In the construction step of the azulene ring we investigated the possibility to vary the 
electrophile in substituting the 1-position using different activated carboxylic acid
derivatives. First, a test reaction was run with acetic anhydride as electrophile to give 1-
acetoxy-6-chloroazulene (85) in 62% yield (Scheme 5). Compound 85 has already been 
reported in the literature and the yield was consistent with the previously reported one.
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The reaction was also applied with succinic anhydride, which gave the carboxylic acid 
derivative 89. The first attempt led to formation of an insoluble material, from which no
product was isolated. Learning from this, the amount of succinic anhydride was reduced 
from five to one equivalent to produce 89 in 14% yield. The result suggests that the excess 
of the anhydride reacts further with the carboxyl group of 89 to form an insoluble residue. 
An additional explanation for the low yield could be the instability of the compound, 
which was found out after purification. The instability might be explained by the free 
carboxyl group, since the corresponding methyl ester derivative 90 is stable.
In addition to acid anhydrides, acyl chlorides and mixed anhydrides were used as 
electrophiles. Benzoyl chloride, nicotinoyl chloride and 2-thiophenecarbonyl chloride 
gave compounds 86, 87 and 88 in 40%, 33% and 40% yield, respectively (Scheme 5).
Mixed anhydrides were prepared from pivaloyl chloride and carboxylic acid derivatives 
and the method produced compounds 90 and 91 in 51% and 25% yield, respectively. In 
the case of 91, the amount of mixed anhydride was reduced from five to two equivalents,
after the first attempt had resulted in the formation of many side products that were
difficult to separate from the desired product. The reaction was also tested with benzyl 
chloroformate as the electrophile resulting in the carbonate 92 in 32% yield. Using 
variable activated carboxylic acid derivatives we have shown that the method enables the 
functionalization of the 1-position with several ester- and carbonate-linked substituents.
Of note, introduction of the desired functionality should be carried out in the azulene ring 
formation step, as instability of the 1-hydroxyazulene intermediate prevents later 
conversion of the ester group to other esters.
3.1.2 Functionalization of the 6-position
The applicability of the methyl group of 6-methylazulene was demonstrated with two 
different approaches, either via a formyl group or by deprotonation with a strong base
(Publication I). We also showed that a chlorine atom in the 6-position can be used in 
palladium-mediated cross-coupling reactions (Publication II).
In the first approach, the methyl group was converted to a formyl group via an 
enamine by applying the method previously described for 1-methoxycarbonyl-4-
formylazulene.135 Starting from 80, 6-formylazulene (94) was obtained in 68% yield over 
two steps (Scheme 6). Previously 94 has been synthesized from an acetal-protected 4-
formylpyridine in an overall yield of 18%.136 Our method gave 94 in an overall yield of 
43% with the same number of synthetic steps and without the additional need of
protecting groups. The versatility of the formyl group in further reactions was 
demonstrated by synthesizing the amino derivative 95 with reductive amination. The 
reaction gave 95 in 82% yield and also the corresponding alcohol 96 was isolated in 11% 
yield.
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Scheme 6 Functionalization of the methyl group of 6-methylazulene via a formyl group.
Reagents and conditions: (a) N,N-Dimethylformamide dimethyl acetal, DMF, 140 
°C, 7 h; (b) NaIO4, THF, H2O, rt, 1 h, 68% from 80; (c) Piperidine, NaBH(OAc)3,
DCM, rt, 5 h, 83% (95), 11% (96).
The second approach for 6-methyl group functionalization was the deprotonation of the 
methyl group of 6-methylazulene with a strong base,90 which enables further reactions 
with various electrophiles. The use of n-butyllithium (n-BuLi) led to decomposition of the
azulene scaffold, but the deprotonation with lithium diisopropylamide (LDA) produced 
the desired anion. Electrophiles were added directly to the reaction mixture after the 
azulene anion was formed. The reaction with benzaldehyde, 4-methoxybenzaldehyde, 
benzyl bromide and ethyl chloroformate gave the alcohols 98 and 99, the phenyl
derivative 97 and the ester 100 in 57%, 23%, 84% and 47% yields, respectively (Scheme 
7). In each case a small amount (≤16%) of 6-methylazulene was left unreacted. The 
differences in the observed yields are not likely caused by the variation of the reactivity 
between the used electrophiles but rather due to the reactivity of the formed products. The 
ester 100 is prone to deprotonation allowing the formed anion to react for second time 
with ethyl chloroformate to give diester 101, which was obtained in 13% yield. 
Compounds 98 and 99 contain a hydroxy group in the benzylic position, and dehydration
leads to a fully conjugated system. Dehydration in the basic reaction conditions is 
probable, although the dehydrated products could not be isolated from the reaction 
mixtures.
Scheme 7 Deprotonation of 6-methylazulene followed by reactions with various electrophiles.
Reagents and conditions: (a) LDA, THF, 0 °C, 10 min and then rt, 20 min, (b)
BnBr, –78 °C → rt, 70 min, 84%; (c) Appropriate benzaldehyde, 0 °C, 10 min and 
then rt, 1.5 h, 57% (98), 23% (99); (d) EtO2CCl, –78 °C → 0 °C, 55 min, 47% 
(100), 13% (101); (e) NaOH, THF, H2O, rt, 2 h, 96%.
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Hydrolysis of the ester gave 102 in 96% yield (Scheme 7). Compound 102 has also been
synthesized previously directly from the deprotonated 6-methylazulene and carbon 
dioxide in a good yield.90 Our method is advantageous compared to the reported method in 
case the following synthetic step requires protection of the carboxyl group, since our 
method produces the ester directly.
The feasibility of the chlorine atom of the 1-acyloxyazulene scaffold in palladium-
mediated cross-coupling reactions was demonstrated with Heck reaction (Publication II).
Since imidazoles are important heterocycles in medicinal chemistry,137 this moiety was 
introduced to the azulene scaffold. The Heck reaction was carried out for both the 
disubstituted azulene 85 and the trisubstituted azulene 103 with 1-trityl-4-vinyl-1H-
imidazole, which gave compounds 104 and 105 in 59% and 67% yield, respectively
(Scheme 8). Subsequently, the trityl groups were removed by trifluoroacetic acid (TFA).
In the reaction mixture ethane-1,2-dithiol (EDT) was used as an additive to trap the 
formed trityl cation, which otherwise could have reacted with other nucleophiles, such as 
the 3-position of 106. However, the use of EDT in the case of 105 led to the mixture of 
products, as 105 contains a formyl group, which was reactive towards EDT. Finally, the 
reaction was performed without EDT to give 107 in 92% yield.
Scheme 8 Demonstration of the versatility of the chlorine atom in palladium-mediated cross-
coupling reactions. Reagents and conditions: (a) 1-Trityl-4-vinyl-1H-imidazole,
P(t-Bu)3HBF4, Et3N, benzene, mw, 160 °C, 30 min, 59% (104), 67% (105); (b) TFA, 
ethane-1,2-dithiol, DCM, rt, 15 min, 91% (106); (c) TFA, DCM, rt, 30 min, 92%
(107).
3.1.3 Functionalization of the five-membered ring
We investigated the possibilities to functionalize the 1- and 3-positions of the five-
membered ring of azulene via synthetic handles. Formyl and iodine substituents are 
versatile synthetic handles, which easily can be introduced to these positions with 
Vilsmeier–Haack formylation88,138 and iodination with N-iodosuccinimide (NIS).139 Due 
to this, we decided to study their use in further functionalization of the five-membered 
ring of azulene together with a chloromethylketone group, which is a feasible synthetic 
handle in the synthesis of heterocycles.140 6-Phenylethylazulene (97) and 1-acetoxy-6-
chloroazulene (85) were selected as test compounds for scoping out these reactions
(Publication I and II).
The monoformylated product 108 was synthesized from 97 in 88% yield after a fast 
Vilsmeier–Haack reaction (Scheme 9). Iodination of 108 with NIS gave the 1,3,6-
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trisubstituted azulene 109 in high 97% yield. Noteworthy, the reactions should be done in
this order, since the mono-iodinated product without a substituent at the 3-position is 
highly unstable and all our attempts to isolate it failed. Additionally, the iodination of the 
unsubstituted five-membered ring of azulene resulted in a mixture of mono- and di-
iodinated compounds as well as unreacted starting material.
Scheme 9 Functionalization of the five-membered ring utilizing iodine and a formyl group as 
synthetic handles. Reagents and conditions: (a) (Chloromethylene)dimethyliminium 
chloride, DCM, 0 °C, 30 min, rt, 45 min, 88%; (b) NIS, DCM, 0 °C, 1 h, 97%; (c) 
An appropriate phenylboronic acid, Pd(dppf)Cl2, BINAP, Cs2CO3, PhMe, mw, 110 
°C, 1-2 h, 80% (110), 78% (111), 24% (112); (d) Piperidine, NaBH(OAc)3, DCM, 
rt, 7 h, 92%; (e) Malonic acid, piperidine, pyridine, mw, 130 °C, 30 min, 39%.
Compound 109 with two useful synthetic handles can be considered as an important
intermediate. The exploitation of the iodine atom in Suzuki cross-coupling reactions was 
demonstrated with three phenylboronic acids with different electronic properties.
Applying the previously reported method141 the reaction gave compounds 110, 111 and 
112 in 80%, 78% and 24% yields, respectively (Scheme 9). Furthermore, the formyl group 
of 110 was converted to a carboxyl and an amino functionality. Knoevenagel condensation 
gave 114 in 39% yield and reductive amination gave 113 in 92% yield.
Next, we studied the possibilities to introduce a chloromethylketone group in the 1-
position of the azulene scaffold. Our first attempt was to introduce it to 6-methylazulene 
with Friedel–Crafts acylation reaction using chloroacetyl chloride and AlCl3. However, 
the reaction gave low yield, from 2% to 25%, most likely since both chlorine atoms in
chloroacetyl chloride are reactive in Friedel–Crafts conditions. Better results were 
obtained applying a modified Vilsmeier–Haack reaction as described by Dragu et al.,142 by
which the compound 115 was obtained in 73% yield (Scheme 10).
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Scheme 10 Introduction of a chloromethylketone group in the 1-position and attempts to 
functionalize the five-membered ring via the intermediate 116. Reagents and
conditions: (a) 2-Chloro-N,N-diethylacetamide, POCl3, 1,4-dioxane, mw, 100 °C, 2 
h, 73%; (b) NIS, DCM, 0 °C, 75 min, 97%; (c) Thiourea, EtOH, mw, 120 °C, 5 min; 
(d) Phenylboronic acid, Pd(dppf)Cl2, BINAP, Cs2CO3, PhMe, mw, 110 °C, 1 h.
We studied the option that synthetic handles are introduced first to the 1- and 3-positions 
before reacting them further. Thus, an iodine atom was introduced to the 3-position of the 
chloromethylketone derivative 115 with NIS in 97% yield (Scheme 10). However, the 
further reactions of either the iodine or the chloromethylketone of compound 116 were 
problematic. Suzuki reaction with phenylboronic acid resulted in a mixture of compounds, 
of which two fractions were separated. The first fraction was a mixture of two compounds, 
which could not be separated from each other. However, NMR and HRMS analysis 
suggested that this fraction consisted of the desired product 118 and its analogue 119,
where the chlorine was replaced by an iodine (combined yield 25–30%). This mixture 
could nonetheless be used in e.g. formation of heterocycles, since both compounds are 
expected to give the same heterocycle. The second fraction contained the dehalogenated 
product 120 in 16% yield. Because of the low yield and the resulting mixture of 
compounds, we decided to try a different approach by first converting the
chloromethylketone group of 116 to aminothiazole. Unfortunately, also this reaction gave 
several products and the desired one could not be isolated from the mixture.
Eventually, the best approach was to synthesize first the thiazole heterocycle from the 
chloromethylketone. Thiourea or thioacetamide were used as a reagent to obtain the 
aminothiazole 121 and the methylthiazole 122 in 92% and 86% yield, respectively
(Scheme 11). Formylation of the 3-position was tested with both thiazole derivatives. The
electron-rich aminothiazole ring caused selectivity problems in this reaction step and the 
desired product 123 could not be isolated from the mixture. Furthermore, 121 turned out 
to be relatively unstable. However, the methylthiazole derivative 124 was obtained in 56% 
yield. One reason for the moderate yield was the fact that approximately one-third of the 
starting material remained unreacted in the reaction. The iodination of the 3-position of 
122 gave a 97% yield. Compound 125 was reacted in Suzuki coupling to produce 126 in
41% yield in the next step.
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Scheme 11 Functionalization of the five-membered ring exploiting a chloromethylketone group.
Reagents and conditions: (a) Thiourea, EtOH, mw, 120 °C, 30 min, 92% (121); (b) 
Thioacetamide, EtOH, mw, 120 °C, 1 h, 86% (122); (c) (Chloromethylene)-
dimethyliminium chloride, DCM, 0 °C, 1 h, 56% (124); (d) NIS, DCM, 0 °C, 30 
min, 97%; (e) Phenylboronic acid, Pd(dppf)Cl2, BINAP, Cs2CO3, PhMe, mw, 110 
°C, 1 h, 41%.
The 3-position of the 1-acyloxyazulene derivatives was substituted by introducing a
formyl group as a synthetic handle (Publication II). 1-Acetoxy-6-chloroazulene (85) was 
used as a test substance as we studied the formylation reaction using both commercial and 
in situ prepared Vilsmeier–Haack reagent (Scheme 12). When the reagent was prepared 
from POCl3 and DMF, the reaction temperature (room temperature or 90 °C) and the 
amount of POCl3 (1.5–4 equiv) were varied. The yields of 103 were between 31% and 
59% and the highest was obtained using two equivalents of POCl3 at room temperature.
Correspondingly the yield was 44% using the commercial reagent in DCM at 0 °C. We 
also noticed that there were variation in the yields when applying the same reaction 
conditions, which was likely caused by ester hydrolysis. To avoid this, NaHCO3 was used
instead of NaOH in the workup.
Scheme 12 Functionalization of the 3-position via a formyl group. Reagents and conditions: (a) 
POCl3, DMF, rt, 45 min, 59%; (b) Morpholine, NaBH(OAc)3, DCM, rt, 2.5 h, 53%; 
(c) BH3·THF, THF, rt, 20 min, quant.
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To demonstrate the feasibility of the formyl group, it was converted to an amino 
functionality by reductive amination, which gave 127 in 53% yield (Scheme 12).
Furthermore, reduction of the formyl group with borane-THF complex gave 128 in
quantitative yield, but it is unstable and decomposes at room temperature already within a 
few days.
3.2 Azulene-based compounds for targeting orexin receptors
In this work two series of compounds for targeting orexin receptors were designed and 
synthesized. With the first series, we aimed at finding azulene-based compounds, which 
act through the orexin receptors (Publication III). The second series of compounds was
designed based on the biological results from the first one in order to find enhanced 
agonist activity on orexin receptors (Publication IV). The two series of compounds are 
discussed together in this chapter.
3.2.1 Designing the compounds for synthesis
We began the design of the azulene-based compounds using computational methods to 
give an idea on which azulene derivatives should be synthesized first. Without any clues 
from computational modeling, the chances of finding interesting bioactivities on orexin 
receptors only by attaching certain functionalities on the azulene scaffold are rather low, 
no matter how relevant the respective functionalities would be on the orexin-A peptide 
itself. We built a virtual library of di- and trisubstituted azulenes (substituents in the 1-, 3-
and 6-positions), which were accessible with our synthetic protocols for 1,3,6-
trisubstituted azulenes (Publications I and II). The selected azulene scaffold substituents 
had varying hydrogen-bonding properties, size, aromaticity, and linker lengths between 
the substituent and the scaffold. Eventually the virtual library consisted of 70 038 azulene-
based compounds with molecular weight being below 500 g/mol.
The virtual library was then docked into the crystal structure of OX2 receptor, based on
the results of the previously developed pharmacophore model to discover orexin receptor 
ligands.59 Similarities between the top-scoring compounds were examined by visual 
inspection. With this approach we noticed that the 1-position was often occupied by a 
benzoyl derivative and the 6-position by primary carboxamide, or the corresponding 
carboxylic acid. We then selected the compounds for synthesis in the first series from the 
visually examined set.
The results from the first series, which is described in detail in the section 3.2.3, 
guided us in the design of the second series of compounds. We were interested in 
identifying new azulene-based compounds, which would show better agonist activity on 
the orexin receptors than the best compounds of the first series. The most promising 
compounds 132 and 152 were used as a starting point for modifications. In addition to the 
enhanced activity, the aim was also to improve the pharmacokinetic properties of the 
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compounds, as the weak agonists from the first series are highly lipophilic and contain 
ester functionality that is sensitive to hydrolysis.
This time we designed the series so that either the benzoyl group in the 1-position was 
modified, or the ester group in the 6-position was replaced by an amide group. When 
designing the compounds, the ester and amide groups in the 6-position were linked
directly to the azulene scaffold (like in 132), since synthetic modifications of the ester 
linked with a methylene group (like in 152) were expected to be problematic (see section 
3.2.2). The planned modifications in the 1-position were attachment of polar substituents 
to the benzoyl group, or replacement of the benzoyl group with other aromatic groups,
amide derivatives or oxoamide derivatives. We also aimed at synthesizing indole 
analogues to assess the significance of azulene scaffold for the observed biological 
activities.
3.2.2 Synthesis of the designed compounds
The designed compounds were synthesized applying the protocols described in the section 
of 3.1. We also developed these synthetic methodologies further, as described in the 
following chapters, as well as synthesized certain indole analogues as refecence 
compounds. The detailed synthetic descriptions can be found in the experimental sections 
of publications III and IV. The synthetic routes to access the first and second series of 
azulene-based compounds are shown in Scheme 13 and Scheme 14, respectively.
We investigated the oxidation of 94 to obtain the ester 130 with the method originally 
developed for benzaldehydes.143 Our first attempt to synthesize the ester 130 directly from 
94, by stirring one equivalent of Oxone in methanol at room temperature for 17 h, ended 
up in formation of an insoluble solid, which appeared to be neither the desired product nor 
the starting material. To avoid this, we decided to oxidize the formyl group first to a 
carboxyl group, and methylate it afterwards. 6-Carboxyazulene (129) was synthesized by 
stirring the aldehyde 94 and Oxone in DMF at room temperature for 3 h in 48% yield. In 
this reaction, 32% of the starting material was also recovered. Extension of the reaction 
time did not increase the yield, even though the starting material was consumed almost 
completely. Finally, the methylation of 129 with iodomethane gave 130 in 96% yield.
In order to add the second benzoyl group to the five-membered ring of 131, we first 
tried to apply the modified Vilsmeier–Haack conditions. However, in these reaction 
conditions the starting material decomposed and the desired product was not observed. 
Thus, Friedel–Crafts acylation was used instead, and the acylation of 131 with benzoyl 
chloride and AlCl3 gave the trisubstituted azulene 136 in 87% yield. Applying the same 
conditions for compound 132 resulted in a low yield of a mixture of 137 and 138. These 
two compounds were inseparable despite several purification attempts by flash 
chromatography. Similarly, the corresponding carboxylic acids 140 and 141 were not 
separable.
Of note, we also observed that the carboxyl group of 154 is prone to decarboxylation. 
Our attempts to convert it to the corresponding primary amide failed and only the 
decarboxylated product 155 was isolated in 85% yield.
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Scheme 13 Synthesis of the designed azulene-based compounds (the 1st series). Reagents and 
conditions: (a) see Scheme 6; (b) Oxone, DMF, rt, 3 h, 48%; (c) K2CO3,
iodomethane, DMF, rt, 45 min, 96%; (d) An appropriate N,N-dimethylbenzamide, 
POCl3, 1,4-dioxane, mw, 100 °C, 3–5 h, 63% (131), 75% (132), 39% (152), 43% 
(153); (e) NaOH, H2O, MeOH, THF, rt, 0.5–28 h, 82% (133), 87% (134), 34% 
(139), 6% (144); (f) i) EDC·HCl, HOBt·H2O, DMF, 0 °C, 15 min, rt, 1 h, ii) NH3
(aq), rt, 2.5–4 h, 87% (135), 35% (150), 85% (155); (g) Benzoyl chloride, AlCl3,
DCM, 0 °C, 30 min, rt, 4–23 h, 87% (136), 73% (156); (h) NIS, DCM, 0 °C, 30 min, 
rt, 3.5 h, 98%; (i) An appropriate phenylboronic acid, Pd(dppf)Cl2, BINAP, 
Cs2CO3, toluene, mw, 110 °C, 1 h, 84% (143), 88% (148); (j) 
(Chloromethylene)dimethyliminium chloride, DCM, 0 °C, 1 h, 61% (145), 15% 
(146); (k) NIS, DCM, 0 °C, 1.5 h, rt, 19 h, 98%; (l) NaOH, H2O, THF, rt, 2 h, 92% 
(149), 78% (154); (m) i) LDA, THF, 0 °C, 10 min, rt, 20 min, ii) Methyl 
chloroformate, –78 °C, 10 min, –78 °C → 0 °C, 45 min, 52%.
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Scheme 14 Synthesis of the designed azulene-based compounds (the 2nd series). Reagents and 
conditions: (a) An appropriate N,N-dimethylbenzamide, POCl3, 1,4-dioxane, mw, 
100 °C, 4–5 h, 22% (157), 18% (158), 44% (159), 31% (160), 29% (161), 0% 
(163); (b) i) 2-Chloro-N,N-diethylacetamide, POCl3, 1,4-dioxane, mw, 100 °C, 2 h,
33%, ii) Thioacetamide, EtOH, mw, 120 °C, 30 min, 71%; (c) i) Oxalyl chloride, 
toluene, rt, 1 h, ii) An appropriate amine, DCM, 10–30 min, 64% (166), 50% (167); 
(d) i) Phosgene, toluene, 80 °C, overnight, ii) An appropriate amine, 0 °C, 15–30 
min, 35% (168), 9% (169), 49% (170), 84% (171); (e) i) EDC·HCl, HOBt·H2O, 
DMF, 0 °C, 15 min, rt, 1 h ii) An appropriate amine derivative, rt, 1–2.5 h, 79% 
(172), 85% (173), 88% (174), 49% (175), 81% (176), 80% (177); (f) NaOH, THF, 
MeOH, H2O, rt, 30 min, 98%; (g) i) EDC·HCl, HOBt·H2O, DMF, 0 °C, 15 min, rt, 1 
h ii) Ethanolamine, rt, 1.5 h, 87%.
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Compounds 157–161 were synthesized with the modified Vilsmeier–Haack method and 
the yields were low or moderate (Scheme 14-I, Method A). The unreacted starting 
material was collected and it was used again in other reactions. However, the re-used 
starting material was not totally pure, because a small amount of 1-chloro-substituted 
starting material was formed in the reaction and it was not separable from the starting 
material with flash chromatography. Due to this, in the case of 161 also the side product 
162 was isolated. We also tried to synthesize 163, but the reaction failed and only 
insoluble solid was formed, most likely due to nucleophilic nitrogen atom in pyridine, 
which also reacts with the chloroiminium ion derivative. Furthermore, the modified 
Vilsmeier–Haack method was used in the synthesis of 164, which was then converted to 
the thiazole 165 (Scheme 14-I, Method B).
Oxalyl chloride has been reported to react with the 1-position of azulene.144 Compound 
130 was first treated with oxalyl chloride at room temperature and then with an 
appropriate amine derivative to provide 166 and 167 in 64% and 50% yield, respectively 
(Scheme 14-I, Method C). We tried to utilize the same method in the synthesis of the 
amides in the 1-position by replacing oxalyl chloride with phosgene. However, phosgene 
was not as reactive as oxalyl chloride and the reaction did not proceed at the room 
temperature. Heating at 80 °C overnight, followed by the addition of an appropriate amine 
derivative gave the amides 168, 170 and 171 in 35%, 49% and 84% yield, respectively 
(Scheme 14-I, Method D). Additionally, the ester 169 was obtained as a side product from 
the reaction of 168, as methanolic ammonia was used in the reaction. The amides 172–177
and 179 were synthesized from the corresponding carboxylic acids 133 and 178 in good 
yields (Scheme 14-II and III).
Methyl indolecarboxylates were used as starting materials in the synthesis of indole 
analogues (Scheme 15). The 1-position of indole derivative was substituted with benzoyl 
group using benzoyl chloride in the presence of triethylamine. Compounds 182 and 183
were obtained in 59% and 22% yields, respectively. Compounds 184 and 185 were 
prepared following the same method, which was used for 131. The method gave a mixture 
of compounds with the desired compounds being obtained only in 2–3% yield, even 
though the reaction time and the amount of N,N-dimethylbenzoylamide were varied. The 
major products were the trisubstituted indoles 186 and 187, isolated in 23% and 48% 
yield, respectively.
Scheme 15 Synthesis of indole derivatives. Reagents and conditions: (a) Benzoyl choride, Et3N, 
DCM, rt, 23 h, 59% (182), 22% (183); (b) N,N-Dimethylbenzamide, POCl3, mw, 
100 °C, 1–3 h, 2% (184), 3% (185), 23% (186), 48% (187).
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3.2.3 Evaluation of the biological activity
The first compound series in biological activity determination consisted of 33 azulene 
derivatives, of which four were tested as mixtures (Publication III). Sixteen of these 
compounds were the synthetic products inspired by virtual screening, and seven were their 
synthetic intermediates. Additionally, eight previously synthesized compounds were
included in this series. The second compound series consisted of 21 azulene-based 
compounds and six indole-based compounds, respectively (Publication IV).
The methods to assess the binding of the compounds to orexin receptors and their 
agonist and potentiation effects are described briefly in the beginning of each section.
More detailed information of the methods used can be found from the publications III and 
IV.
3.2.3.1 Orexin receptor binding
The binding of the compounds to the orexin receptors was evaluated at 10 μM 
concentration with a competition binding assay in Chinese hamster ovary-K1 (CHO) cells 
heterologously expressing of human OX1 and OX2 receptors, using 1 nM [125I]-orexin-A
as the radioligand. Inhibitory constants (Ki) were determined using a Ca2+ elevation assay.
The binding was evaluated only for the first compound series, as we focused on studying
the agonist activity with the second series.
Twelve compounds (86–88, 91, 92, 107, 127, 133, 145–147, 155) of the first series
showed clear (inhibition >30%) and statistically significant inhibition of [125I]-orexin-A
binding to either one or both receptor subtypes (Table 2). Ki values were determined for 
the two most promising binders 127 and 147, and they were in low micromolar range for 
both receptor subtypes.
Unexpectedly, six compounds (132, 134, 142, 144, 152, 153) increased significantly
the binding of [125I]-orexin-A to OX1 receptor in the binding assay. Similar effect has been 
noticed also previously with weak small-molecular agonists.59 Additionally, the 
extracellular Ca2+ is known to stimulate the OX1 receptor signaling and orexin-A binding 
to OX1 receptor.145–147 The potentiation of orexin-A response to these compounds was 
studied further and will be discussed more in detail in section 3.2.3.3, but in short: 144
was the only compound to increase the [125I]-orexin-A binding without inducing Ca2+
elevation or acting as a potentiator of orexin-A at 10 μM concentration. Due to this, 144
was further examined by determining Ki values (Table 2) and the Ca2+ responses at 
concentrations exceeding 10 μM (Figure 14).
Even though the number of the tested compounds is relatively low, the series of 
compounds is congeneric, which could allow preliminary structure-activity relationships
(SARs) examination. However, our compound series contained both weak orexin receptor 
agonists and compounds potentiating the response of orexin-A to orexin receptors. Weak 
agonists and potentiators have an effect on the binding results, which hampers the 
interpretation of the binding results (see publication III for more information).
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Table 2 Screening results of the orexin receptor binding and activation of the first series
compounds and Ki values for 127, 144 and 147.
Inhibition (%) of [125I]-orexin-A
binding at 10 μMa
Ki (μM) Ca2+ elevation at 10 μM 
(% of Emax of orexin-A)b
Compound OX1R OX2R OX1R OX2R OX1R OX2R
147 40.7 ± 13.0 * 47.2 ± 6.8 * 4.8 ± 1.8 3.6 ± 1.1 1.6 ± 0.7 0.7 ± 0.7
127 24.5 ± 10.7 * 46.7 ± 10.7 * 7.6 ± 2.0 8.6 ± 2.8 0.4 ± 0.3 –1.0 ± 0.4
146 37.8 ± 6.0 * 44.1 ± 9.5 * n.d. n.d. 1.8 ± 0.7 3.5 ± 0.9
107 23.0 ± 4.8 * 39.9 ± 7.1 * n.d. n.d. 2.4 ± 1.0 0.4 ± 1.3
145 25.0 ± 9.7 * 37.2 ± 11.1 * n.d. n.d. 3.1 ± 1.2 2.3 ± 0.5
91 –4.5 ± 2.5 * 36.0 ± 7.6 * n.d. n.d. 1.6 ± 0.2 –1.0 ± 0.1
92 18.2 ± 2.8 * 35.6 ± 4.1 * n.d. n.d. 0.5 ± 0.6 –2.7 ± 0.7
86 0.1 ± 12.9 34.3 ± 9.1 * n.d. n.d. 0.1 ± 0.7 –3.3 ± 0.5
88 9.8 ± 10.8 33.2 ± 10.2 * n.d. n.d. 0.9 ± 0.6 –2.7 ± 0.8
133 11.0 ± 16.5 32.9 ± 12.0 * n.d. n.d. 2.2 ± 1.5 2.3 ± 2.6
87 –2.4 ± 12.5 32.3 ± 9.2 * n.d. n.d. 0.6 ± 0.4 0.6 ± 0.4
155 38.3 ± 0.8 * 31.0 ± 15.6 n.d. n.d. 0.6 ± 0.9 –0.4 ± 0.6
131 7.2 ± 17.2 28.9 ± 8.5 * n.d. n.d. 4.2 ± 2.1 4.9 ± 1.5
139 –10.4 ± 6.1 27.0 ± 12.5 n.d. n.d. –1.4 ± 1.1 –2.1 ± 0.9
137/138c 18.3 ± 8.5 * 26.4 ± 7.8 * n.d. n.d. 0.7 ± 1.0 –0.1 ± 0.1
140/141c 19.9 ± 11.3 * 25.6 ± 8.8 * n.d. n.d. –1.4 ± 1.1 –3.2 ± 0.4
90 8.0 ± 7.0 24.3 ± 4.2 * n.d. n.d. 0.7 ± 0.4 –2.1 ± 0.7
149 16.2 ± 8.1 * 21.5 ± 10.1 * n.d. n.d. 0.8 ± 0.2 –0.2 ± 0.6
143 8.4 ± 12.3 19.1 ± 9.6 n.d. n.d. 1.5 ± 0.2 –0.2 ± 0.4
135 13.6 ± 10.5 18.0 ± 13.9 n.d. n.d. 0.4 ± 1.1 1.3 ± 2.0
150 6.1 ± 8.5 16.7 ± 11.8 n.d. n.d. 0.6 ± 0.9 1.7 ± 0.1
154 8.6 ± 13.3 11.2 ± 10.4 n.d. n.d. 0.2 ± 0.5 –1.1 ± 0.6
148 8.5 ± 8.9 1.8 ± 3.4 n.d. n.d. 0.8 ± 0.1 –0.3 ± 0.3
134 –81.5 ± 18.6 * 1.0 ± 5.8 n.d. n.d. 1.1 ± 0.7 3.0 ± 0.8
153 –30.4 ± 10.6 * 1.0 ± 3.6 n.d. n.d. 1.3 ± 0.1 0.4 ± 0.7
152 –37.7 ± 8.1 * –4.3 ± 18.7 n.d. n.d. 5.0 ± 0.6 11.0 ± 1.2
142 –34.9 ± 2.1 * –5.4 ± 8.2 n.d. n.d. 1.2 ± 0.4 –0.3 ± 0.1
136 –10.6 ± 16.1 –14.5 ± 12.4 n.d. n.d. –0.6 ± 0.9 –1.5 ± 0.4
144 –24.0 ± 4.8 * –16.9 ± 16.4 7.5 ± 0.9 4.9 ± 2.0 –0.2 ± 0.8 –1.0 ± 1.4
156 –21.4 ± 11.9 –20.4 ± 11.2 n.d. n.d. 0.3 ± 0.6 0.1 ± 0.2
132 –60.5 ± 19.8 * –47.4 ± 11.4 * n.d. n.d. 6.1 ± 0.6 12.4 ± 0.5
*: P < 0.05; n.d. = not determined; a n = 3–4; b n = 2; c A 47:53 mixture of two compounds.
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Based on the binding data, a slight trend seems to be that the compounds with the carboxyl 
group in the 6-position have better binding to the receptors, compared to the 
corresponding ester derivatives (e.g compounds 145 vs. 146, and 148 vs. 149).
Noteworthy, the opposite applies for the potentiators: the ester derivatives seem to be 
better potentiators than the corresponding carboxylic acid derivatives (e.g. 136 vs. 139,
and 153 vs. 154). It might be that the carboxyl group in the 6-position enhances the 
binding of the compounds to the orthosteric orexin-A binding site or the potentiation 
effect of the ester derivatives hides the competition between the compound and [125I]-
orexin-A. Due to this, compounds with the ester group in the 6-position might bind better 
to OX1 receptor than the binding data suggest.
The determination of Ki values for all compounds could help the interpretation of the 
binding results. However, we assessed them only for three compounds, as our main focus 
in this study was to find agonists not antagonists. Intensive research on orexin receptor 
antagonists have resulted in many reported antagonists, with the most potent ones having 
Ki values in the low nanomolar range (see section 1.1.2).
3.2.3.2 Agonist activity
The agonist activities of the compounds were screened in the Ca2+ elevation assay at 10 
μM concentration, and the Ca2+ elevation was compared to the maximum response (Emax)
of orexin-A. As part of the response, or even the whole response, could derive from the 
nonspecific response, the Ca2+ responses of the compounds were determined in the 
presence of an excess of a known orexin receptor antagonist, SB-334867148 for OX1R and 
TCS-1102149 for OX2R, respectively, to identify the magnitude of the nonspecific 
response. Subtracting the nonspecific response from the total Ca2+ elevation gave the Ca2+
elevation caused by the orexin receptor activation. For certain compounds, also the 
concentrated-dependent Ca2+ elevation was assessed using 10 μM, 18 μM and 32 μM 
concentrations, and 45 μM for 144 only. These compounds were also tested on control 
CHO-K1 cells to verify the orexin receptor specific response.
When screening the agonist activities of the first series, we noticed that three 
compounds, 131, 132 and 152, induced Ca2+ elevation, which was 5–12% of Emax of 
orexin-A, on both receptor subtypes (Table 2). The orexin receptor-mediated response was 
then determined from these three compounds. Compounds 132 and 152 induced
approximately 5% Ca2+ elevation of Emax of orexin-A via OX2 receptor, but 131 caused 
only nonspecific Ca2+ elevation at 10 μM concentration (Figure 13). These results indicate






















































Figure 13 Orexin receptor-mediated and total Ca2+ responses of 131, 132 and 152. (n = 3–4)
The agonist activity screening results for the second series of azulene-based compounds 
and indole derivatives are shown in Table 3. The determined total Ca2+ responses were 
promising, as 167 and 177 induced Ca2+ elevation, which was 11–18% of Emax of orexin-A
at 10 μM, on both receptor subtypes. The Ca2+ responses of these compounds were 
noticeably higher than the responses determined with the best compounds of the first 
series. Unfortunately, after screening the second series of compounds in the presence of 
orexin receptor antagonists, most of the observed Ca2+ responses appeared to be 
nonspecific and not orexin receptor-mediated. Of note, none of the indole analogues 
showed orexin receptor-mediated Ca2+ elevation, and 182 was the only one to induce Ca2+
elevation at all. This was expected, since their closest azulene analogues, 131 and 136, did 
not show orexin receptor activation either.
Altogether the concentration-dependent Ca2+ responses were determined for four 
compounds. Compound 132 was among the most promising compounds in the first series 
and used as a starting point for the second series of azulene-based compounds. In the 
second series, 177 and 179 showed the highest orexin receptor-mediated Ca2+ elevation at 
10 μM concentration. The selection of 144 is justified in section 3.2.3.1. All tested 
compounds showed concentration-dependent orexin receptor-mediated Ca2+ elevation 
(Figure 14).
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Table 3 Screening results of the orexin receptor activation of the second compound series.
Ca2+ elevation at 10 μM (% of Emax of orexin-A)a
Total Ca2+ responses Orexin receptor-mediated Ca2+ responses
Compound OX1R OX2R OX1R OX2R
157 0.6 ± 0.8 1.2 ± 1.9 0.1 ± 0.8 0.4 ± 1.5
158 0.6 ± 0.0 0.1 ± 0.6 –0.1 ± 0.2 –1.0 ± 0.5
159 0.5 ± 0.3 0.7 ± 0.8 –0.2 ± 0.4 –0.2 ± 0.7
160 3.4 ± 1.1 4.9 ± 1.4 –2.6 ± 1.0 –1.5 ± 1.3
161 2.0 ± 1.9 –0.3 ± 0.5 1.4 ± 1.5 –1.1 ± 0.3
162 –0.4 ± 0.9 0.1 ± 1.1 –1.4 ± 0.6 –0.9 ± 1.2
165 0.9 ± 1.4 3.0 ± 0.9 –1.5 ± 1.2 1.3 ± 0.9
166 –0.4 ± 1.1 1.0 ± 0.9 –1.6 ± 0.7 –1.0 ± 0.3
167 11. 4 ± 3.0 13.6 ± 2.1 –4.3 ± 1.2 1.5 ± 1.5
168 –0.2 ± 1.2 0.9 ± 1.1 –1.6 ± 0.9 –0.3 ± 1.3
169 1.1 ± 1.1 2.6 ± 1.1 –2.3 ± 0.7 –0.1 ± 0.3
170 0.3 ± 1.2 0.9 ± 1.2 –0.8 ± 0.8 –0.1 ± 1.1
171 1.8 ± 1.1 2.5 ± 1.4 –0.4 ± 0.3 1.1 ± 1.0
172 1.2 ± 2.3 0.6 ± 3.4 –3.3 ± 1.4 –6.6 ± 1.8
173 2.5 ± 0.6 5.7 ± 1.1 0.1 ± 0.4 0.7 ± 1.0
174 1.2 ± 1.0 2.6 ± 1.3 –0.7 ± 0.3 –1.7 ± 1.5
175 2.3 ± 0.3 0.1 ± 1.3 0.3 ± 0.9 –1.6 ± 0.2
176 2.7 ± 0.4 2.6 ± 0.6 0.4 ± 0.4 –1.3 ± 0.6
177 11.1 ± 0.2 17.7 ± 1.3 2.2 ± 0.1 0.1 ± 2.4
178 0.1 ± 0.4 0.8 ± 0.4 –0.7 ± 0.5 –0.7 ± 0.9
179 5.8 ± 0.3 8.4 ± 1.3 1.0 ± 0.3 3.1 ± 1.9
182 0.9 ± 0.3 4.6 ± 0.6 –7.0 ± 3.0 –1.1 ± 2.5
183 –1.2 ± 0.2 0.2 ± 0.8 –3.7 ± 1.5 –2.1 ± 0.4
184 –0.6 ± 0.3 0.5 ± 0.3 –2.1 ± 0.6 –1.0 ± 0.5
185 –0.5 ± 0.4 0.8 ± 0.7 –2.5 ± 0.4 –0.2 ± 0.3
186 –1.1 ± 0.5 0.8 ± 0.8 –4.0 ± 1.3 –2.1 ± 1.5
187 –0.7 ± 0.2 1.2 ± 0.8 –4.1 ± 1.4 –1.7 ± 1.42
a n = 3–4.
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Figure 14 Orexin receptor-mediated and total Ca2+ responses of 132, 144, 177 and 179 at three 
different concentrations. (n = 3–6)
In this study, we have identified novel azulene-based weak orexin receptor agonists. 
Compounds 132 and 152 from the first compound series gave the best OX2-mediated Ca2+
responses at 10 μM. Compound 179 was the most promising one in the second series, and
its specific Ca2+ responses at tested concentrations were of similar magnitude (slightly 
lower) than those of 132. Furthermore, 179 is not as hydrophobic and it possesses
improved solubility compared to 132 or 152. Additionally, 144 showed orexin receptor-
mediated Ca2+ elevation only at the highest concentrations (32 μM and 45 μM), but unlike 
132, 177 and 179, the trend of the responses was clearly increasing at the highest 
concentrations. Althogether, 144 showed the highest determined Ca2+ responses in this 
study. At 45 μM concentration it induced Ca2+ responses, which were approximately 18% 
of the Emax for orexin-A, on both receptor subtypes.
Since only a few synthesized compounds showed agonist activity, and for the ones that 
did, the activity was weak. Therefore, it is difficult to make conclusions regarding the
structure-activity relationships from the available data. Even though the identified agonist 
activities are weak, the compounds increase the knowledge of molecules acting as orexin 
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receptor agonists. Currently only one series of reported orexin receptor agonists are clearly 
more potent than our new compounds.
3.2.3.3 Potentiation of orexin-A response
The potentiation effect was studied by assessing the Ca2+ responses of the compounds in 
the presence of 0.02–0.03 nM orexin-A (corresponding to EC20 of the orexin-A) at 10 μM 
concentration. We used controls (10 nM or 30 nM ATP) to mimic the Ca2+ effect of the 
tested compounds, as changes in intracellular Ca2+ levels might potentiate the orexin-A
response. To prove that the potentiation effect is transmitted through the orexin receptors, 
the effects of compounds on the actions of ATP in orexin receptor-expressing cells were 
tested with assay set-up identical to the one used with orexin-A. ATP causes a Ca2+
response similar to orexin-A, but the response is not orexin receptor-mediated.
The potentiation effect was studied with twelve compounds from the first series: six of
them (132, 134, 142, 144, 152, 153) increased significantly the binding of [125I]-orexin-A
to OX1R in the binding assay, and other six compounds (131, 133, 136, 139, 154, 156)
potentiated [125I]-orexin-A binding to OX1R on some of the individual experiments. With 
the exception of 144, all tested compounds potentiated the observed orexin-A response at 
least 1.4-fold on OX1 receptors at 10 μM concentration (Figure 15). When comparing the 
potentiation to the controls, the effect of eight compounds (133, 134, 136, 139, 142, 153,
154, 156) was significant, and 153 was the only one showing potentiation also on OX2
receptors (ca. 1.3-fold). The potentiation induced by the compounds 131, 132 and 152 was 
not significant when compared to the control (30 nM ATP), indicating these compounds
induced an indirect potentiation of orexin-A response by increasing the intracellular Ca2+
levels. However, the detection of the potentiation effect might be too challenging in the 
case the compound induces Ca2+ elevation itself as well.
We evaluated further the three most promising OX1 receptor potentiators 136, 142, 153
by assessing their concentration-dependency effects (Figure 15). Compound 153 appeared 
to be best potentiator with increasing the orexin-A response 1.4-fold at 5 μM and 2.0-fold 
at 10 μM concentrations. The detected potentiation effects are most likely orexin receptor-
mediated, as the compounds did not affect the ATP response in OX1 receptor-expressing 
cells (Figure 15).
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Figure 15 A. The effects of the compounds from the first series at 10 μM concentration on Ca2+
responses elicited by 0.02–0.03 nM orexin-A. Controls, 10 nM or 30 nM ATP, 
mimicked the Ca2+ effects of the tested compounds. 10 nM ATP was used for 133,
134, 136, 139, 142, 144, 153, 154, 156, and 30 nM ATP for 131, 132, 152. B. The
effects of 136, 142, 153 at three different concentrations on Ca2+ responses elicited by 
0.02–0.03 nM orexin-A or 60 nM ATP (corresponding to the EC20 of each ligand). ns
= not significant (P > 0.05), *P < 0.05, **P < 0.01, ***P < 0.001; n = 3–4.
In the case of the second compound series, we tested the potentiation effect of all six
indole derivatives and three azulene-based compounds (157, 158, 178). The azulene 
derivatives were selected as close but more hydrophilic analogues compared to the first 
series compounds, 131 and 133, which also showed some potentiation of the orexin-A
response to OX1R, even though the effect of 131 might be indirect.
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Four of six indole derivatives (182, 185, 186, 187) potentiated the Ca2+ response to 
orexin-A on OX1R (Figure 16). Compound 182, an indole analogue of 131, gave the best 
response, but when the results were compared to controls, the effect of 182 was not 
significant. Compound 182 induces nonspecific Ca2+ elevation similarly to 131, and the 
effect is most likely indirect. Compounds 186 and 187 gave the best significant responses 
(1.7-fold), not surprisingly, as their azulene analogue 136 was one of the most promising 
potentiator of the first series. Furthermore, all three tested azulene derivatives of the 
second series showed potentiation of orexin-A responses on OX1R, but the effect was not 
as good as the best compounds in the first series.
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Figure 16 The effects of indole derivatives and three azulene-based compounds from the second
series at 10 μM concentration on Ca2+ responses elicited by 0.02–0.03 nM orexin-A.
10 nM ATP was used as a control for all compounds, except for 182. ns = not 
significant (P > 0.05), *P < 0.05, **P < 0.01; n = 3–4.
As pointed out in the section 3.2.3.1, the methyl ester group in the 6-position of azulene 
seems to be preferred over the carboxyl group for the potentiation effect of orexin-A.
Furthermore our results demonstrate that when azulene scaffold is replaced by indole, 
these analogues have similar effects on the Ca2+ responses to orexin-A on OX1 receptors
(e.g. 136 vs. 186, and 131 vs. 182).
The orexin-A potentiation effect of the compounds can be considered as the most 
interesting finding in the biological evaluation of the synthesized azulene derivatives,
since only one series of orexin receptor potentiators has been reported before us.60 The
observed potentiation effect of our best compounds was similar to the previously reported 
potentiators. However, the results are not fully comparable, as the evaluation methods 
differ from each other.
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4 Summary and conclusions
This thesis describes the design, synthesis and biological evaluation of novel azulene-
based compounds for targeting orexin receptors. Our approach was to develop general 
regioselective synthetic protocols for trisubstituted azulenes possessing the desired 1,3,6-
trisubstitution pattern. We built a virtual library from chemically diverse azulene-based 
compounds that can be synthesized with the developed methods. By doing so we avoided 
getting a virtual screening hitlist, which contains synthetically useless compounds, or 
compounds whose synthesis would require several routes.
To access the differently substituted azulenes, the study was started by developing two 
general synthetic routes for 1,3,6-trisubstituted azulenes. Both methods began from 
inexpensive and readily available starting materials, and the azulene scaffold was formed 
first. We optimized the previously reported synthetic methods to obtain the azulene 
scaffold in higher yields. In our methods, the regioselective substitution of the azulene 
scaffold with versatile synthetic handles allows easy variation of the substituents. The 
efficiency of the synthetic routes was demonstrated with test substances, whose synthesis 
gave good overall yields.
The virtual library was docked into the crystal structure of OX2R. The first series of 
compounds for biological activity determination was selected and synthesized after visual 
inspection of the virtual screening results. Most of the selected compounds were 
synthesized via the developed methods. The applicability of the synthetic methods with 
other top-scoring compounds was not studied, since in the second compound series we 
focused on further development of the first series hits. However, already the synthesis of 
the two compound series highlights the efficiency of the synthetic methods.
Altogether, the biological activity towards orexin receptors was determined from 54 
azulene-based compounds and six indole derivatives. The main focus of this study was to
discover orexin receptor agonists based on the azulene scaffold. We identified five novel 
azulene derivatives (132, 144, 152, 177, 179) as weak orexin receptor agonists (Figure 
17). The first series hits, 132 and 152, were highly lipophilic and we aimed at reducing the 
lipophilicity in the second compound series. As a result, we obtained 179 with improved 
solubility and retained agonist activity.
We identified 144 with the best Ca2+ response among all the tested compounds, despite 
it showed agonist activity only at the two highest concentrations. The detected Ca2+
elevation was approximately 18% of the Emax of orexin-A on both receptor subtypes. 
Thus, it is possible that also other compounds in our series behave similarly, showing
agonist activity at higher concentrations than those used in the screening. Although we did 
not discover highly potent agonists in this study, our results extend the knowledge of 
small-molecular activating ligands for orexin receptors. During the agonist development,
we also identified novel antagonists of the orexin receptors. The two most promising 
compounds, 127 and 147, had Ki values in the low micromolar range (Figure 17).
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Figure 17 The most promising (I) agonists, (II) antagonists and (III) potentiators identified in 
this study.
The most interesting result in the biological evaluation was a set of azulene derivatives
potentiating the response of orexin-A on OX1 receptor. Three compounds (136, 142, 153)
showed concentration-dependent potentiation and they increased the orexin-A response at 
10 μM two-fold, which is comparable with the potentiation effect observed with the only 
previously reported orexin receptor potentiators (Figure 17). Small-molecular potentiators 
of orexin receptor signaling could have similar applications than agonists in conditions
caused by low levels of endogenous orexin peptides. Further research is needed to better 
understand the potentiation phenomenon, and to develop more effective potentiators.
The biological responses of the indole derivatives resembled those of the
corresponding azulene analogues. Indoles 186 and 187 (analogues of azulene derivative
136) potentiated the effects of orexin-A, but none of the indole derivatives induced orexin 
receptor-mediated Ca2+ elevation. The potentiation effect of the azulene 136 seemed 
slightly better compared to its indole analogues, with two possible explanations. Either the
spatial arrangement of the substituents on the azulene scaffold is more favorable than on 
the indole scaffold, or the azulene ring itself has stronger interactions with the target than 
indole. Altogether these results support the idea that azulene can be considered as the
isostere of indole.
Identification of novel agonists, antagonists and potentiators on orexin receptors
justifies the strategy followed in the study. To further evaluate the success of the virtual 
screening and the applicability of the developed protocols in the synthesis of the virtual 
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library compounds, more top-scoring compounds should be synthesized. The biological 
activities of the discovered azulene-based compounds are still relatively weak, which 
emphasizes the need of more potent compounds with improved pharmacokinetic 
properties. In addition, new compounds would be essential for establishment of the 
structure-activity relationships.
To best of our knowledge, azulene-based compounds have not been studied on the 
orexin receptors previously. Thus, our azulene-based compounds open an unexplored 
chemical space and provide a new, interesting starting point for the development of small-
molecular compounds acting through the orexin receptors. Our results also encourage 
medicinal chemists to use the azulene scaffold unprejudicedly in drug discovery.
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